Symbols

DARE

Dare Bioscience·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 2

Stock Price Surged Significantly

MACD Golden Cross

EPS Beats Expectation

Dark Cloud Cover

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About DARE

Dare Bioscience, Inc.

A leader in women's health innovation

Industry

Pharmaceutical

Established Date

Listing Date

04/10/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.darebioscience.com

Security Type

Common stock

Office address

3655 Nobel Drive Suite 260 San Diego CA 92122

Business

Introduction

Dare Bioscience, Inc., was incorporated in Delaware in December 2005. The company is a goal-oriented health biotechnology company focused on closing the gap in women's health between promising scientific and real-world solutions. Every innovation the company advances is based on advanced science and supported by rigorous peer-reviewed research. From contraception to menopause, from pelvic pain to fertility, from vaginal health to infectious diseases, the company is trying to use the science that meets her needs to close critical gaps in care.

Company Financials

EPS

DARE has released its 2025 Q4 earnings. EPS was reported at 0.03, versus the expected -0.44, beating expectations. The chart below visualizes how DARE has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

DARE has released its 2025 Q4 earnings report, with revenue of 1.02M, reflecting a YoY change of 1708.36%, and net profit of -1.44M, showing a YoY change of 73.82%. The Sankey diagram below clearly presents DARE's revenue sources and cost distribution.